<p>Prime Medicine, Inc.（纳斯达克代码：PRME - 获取免费报告）在周三的午盘交易中股价上涨了 8.4%。该股最高交易价为 4.52 美元，最后交易价为 4.51 美元。在午盘交易中，共成交 1,555,082 股，较平均交易量 3,151,651 股下降了 51%。该股此前收盘价为 4.16 美元。</p>
<p>获取 <strong>Prime Medicine</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>多位股票分析师最近对该股进行了评论。Lifesci Capital 在 12 月 23 日的研究报告中将 Prime Medicine 的股票评级上调至 “强力买入”。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Prime Medicine 股票的 “卖出（d-）” 评级。最后，Wall Street Zen 在 11 月 8 日的研究报告中将 Prime Medicine 的评级从 “持有” 下调至 “卖出”。一位股票研究分析师给予该股 “强力买入” 评级，另一位则对该公司发布了 “卖出” 评级。根据 MarketBeat 的数据，Prime Medicine 目前的共识评级为 “适度买入”。</p>
<p><strong>查看我们最新的 PRME 股票报告</strong></p>
<h2>Prime Medicine 股票上涨 5.5%</h2>
<p>该公司的 50 日移动平均价格为 3.76 美元。该公司的市值为 7.9244 亿美元，市盈率为-3.05，贝塔值为 2.71。</p>
<p>Prime Medicine（纳斯达克代码：PRME - 获取免费报告）最近于 11 月 7 日公布了季度财报。该公司报告每股收益（EPS）为（0.32 美元），低于分析师的共识预期（0.28 美元）0.04 美元。该季度的收入为 123 万美元。Prime Medicine 的净利润率为-3,301.64%，股本回报率为-163.51%。</p>
<h2>关于 Prime Medicine</h2>
<p>（获取免费报告）</p>
<p>我们是一家生物技术公司，致力于提供一种新型的差异化一次性治愈基因疗法——Prime Editors，以通过部署我们的 Prime Editing 技术来解决最广泛的疾病谱系。我们认为这种技术是一种多功能、精确、高效且广泛的基因编辑技术。与疾病相关的基因突变多种多样，可能从单个碱基的错误（称为点突变）到超出单个碱基的错误，例如插入、缺失、重复或其组合。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Prime Medicine</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>将这些代码输入你的普通经纪账户</li>
<li>这个 AI 机会旨在随着需求的发展而演变</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
<p>在你考虑投资 Prime Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Prime Medicine 并不在名单上。</p>
<p>虽然 Prime Medicine 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRME

<p>Prime Medicine (NASDAQ:PRME) 的股价上涨了 8.4%，达到 4.51 美元，尽管交易量下降了 51%。分析师们的意见不一，Lifesci Capital 给予其 “强力买入” 评级，而 Weiss Ratings 则维持 “卖出” 评级。该公司报告的季度每股收益为（-0.32 美元），未达到预期，市值为 7.9244 亿美元，市盈率为 -3.05。Prime Medicine 专注于使用 Prime Editing 技术进行创新的基因疗法。目前，在分析师中，它的共识评级为 “适度买入”，但一些人建议更好的投资选择</p>

<p>Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s share price traded up 8.4% during mid-day trading on Wednesday . The stock traded as high as $4.52 and last traded at $4.51. 1,555,082 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 3,151,651 shares. The stock had previously closed at $4.16.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.（纳斯达克代码：PRME - 获取免费报告）在周三的午盘交易中股价上涨了 8.4%。该股最高交易价为 4.52 美元，最后交易价为 4.51 美元。在午盘交易中，共成交 1,555,082 股，较平均交易量 3,151,651 股下降了 51%。该股此前收盘价为 4.16 美元。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prime Medicine</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of equities analysts have recently commented on the stock. Lifesci Capital raised shares of Prime Medicine to a &#34;strong-buy&#34; rating in a research report on Tuesday, December 23rd. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Prime Medicine in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded Prime Medicine from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Prime Medicine presently has a consensus rating of &#34;Moderate Buy&#34;.</p>
<div class="lb-trans"><p>多位股票分析师最近对该股进行了评论。Lifesci Capital 在 12 月 23 日的研究报告中将 Prime Medicine 的股票评级上调至 “强力买入”。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Prime Medicine 股票的 “卖出（d-）” 评级。最后，Wall Street Zen 在 11 月 8 日的研究报告中将 Prime Medicine 的评级从 “持有” 下调至 “卖出”。一位股票研究分析师给予该股 “强力买入” 评级，另一位则对该公司发布了 “卖出” 评级。根据 MarketBeat 的数据，Prime Medicine 目前的共识评级为 “适度买入”。</p>
</div><p><strong>View Our Latest Stock Report on PRME</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 PRME 股票报告</strong></p>
</div><h2>Prime Medicine Stock Up 5.5%</h2>
<div class="lb-trans"><h2>Prime Medicine 股票上涨 5.5%</h2>
</div><p>The firm's 50-day moving average price is $3.76. The firm has a market cap of $792.44 million, a PE ratio of -3.05 and a beta of 2.71.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 3.76 美元。该公司的市值为 7.9244 亿美元，市盈率为-3.05，贝塔值为 2.71。</p>
</div><p>Prime Medicine (NASDAQ:PRME - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.04). The firm had revenue of $1.23 million during the quarter. Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 163.51%.</p>
<div class="lb-trans"><p>Prime Medicine（纳斯达克代码：PRME - 获取免费报告）最近于 11 月 7 日公布了季度财报。该公司报告每股收益（EPS）为（0.32 美元），低于分析师的共识预期（0.28 美元）0.04 美元。该季度的收入为 123 万美元。Prime Medicine 的净利润率为-3,301.64%，股本回报率为-163.51%。</p>
</div><h2>About Prime Medicine</h2>
<div class="lb-trans"><h2>关于 Prime Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.</p>
<div class="lb-trans"><p>我们是一家生物技术公司，致力于提供一种新型的差异化一次性治愈基因疗法——Prime Editors，以通过部署我们的 Prime Editing 技术来解决最广泛的疾病谱系。我们认为这种技术是一种多功能、精确、高效且广泛的基因编辑技术。与疾病相关的基因突变多种多样，可能从单个碱基的错误（称为点突变）到超出单个碱基的错误，例如插入、缺失、重复或其组合。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>This AI Opportunity Was Built to Evolve With Demand</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Prime Medicine</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>将这些代码输入你的普通经纪账户</li>
<li>这个 AI 机会旨在随着需求的发展而演变</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Prime Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Prime Medicine 并不在名单上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prime Medicine 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Prime Medicine（NASDAQ:PRME）股价上涨 8.4% - 你是否应该买入？